| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4025938 | Ophthalmology | 2014 | 7 Pages |
Abstract
Treatment with intravitreal aflibercept provided significant functional and anatomic benefits after 52 weeks as compared with sham. The improvements achieved after 6 monthly doses at week 24 largely were maintained until week 52 with as-needed dosing. Intravitreal aflibercept generally was well tolerated.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jean-François MD, Frank G. MD, Johann MD, Yuichiro MD, Christian MD, Ursula MD, Katrin MD, Miki MD, Robert MD, Alyson J. MD, PhD, Florian MS, Brigitte MD, Oliver MD, Rupert MD, GALILEO Study Group GALILEO Study Group,